Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.98 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.98 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their ongoing commitment to research and development. There was no specific guidance provided for future earnings.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical trials and product development.
Madrigal Pharmaceuticals reported a loss of $0.98 per share, with no revenue figures disclosed. The stock reacted positively, rising 0.66%, likely due to investor optimism about ongoing clinical trials and product development despite the lack of detailed financial guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019